AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas

References

• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265–276.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–1861.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–1545.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. How I treat "double hit" lymphoma. Blood. 2017;130(5):590–596.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent < em > BCL2</em > and < em > MYC</em > translocations: the critical factors associated with survival. Blood. 2009;114(11):2273–2279.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Miura I, et al. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009;23(4):777–783.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Gaidano G, Botto B, et al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Ann Oncol. 1998;9(1):55–61.
   PubMed Web of Science ®Google Scholar
• Woessmann W, Zimmermann M, Meinhardt A, et al. Progressive or relapsed burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy. Blood. 2020;135(14):1124–1132.
   PubMed Web of Science ®Google Scholar
• Czabotar PE, Lessene G, Strasser A, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49–63.
   PubMed Web of Science ®Google Scholar
• Monni O, Franssila K, Joensuu H, et al. BCL2 overexpression in diffuse large B-Cell lymphoma. Leuk Lymphoma. 1999;34(1-2):45–52.
   PubMed Web of Science ®Google Scholar
• Tsuyama N, Sakata S, Baba S, et al. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood. 2017;130(4):489–500.
   PubMed Web of Science ®Google Scholar
• Wenzel SS, Grau M, Mavis C, et al. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia. 2013;27(6):1381–1390.
   PubMed Web of Science ®Google Scholar
• Cho-Vega JH, Rassidakis GZ, Admirand JH, et al. MCL-1 expression in B-cell non-Hodgkin’s lymphomas. Hum Pathol. 2004;35(9):1095–1100.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Tambaro FP. How I manage CLL with venetoclax-based treatments. Blood. 2020;135(17):1421–1427.
   PubMed Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-Human study of venetoclax in patients with relapsed or refractory Non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–833.
   PubMed Web of Science ®Google Scholar
• Choudhary GS, Al-Harbi S, Mazumder S, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6(1):e1593.
   PubMedGoogle Scholar
• Tahir SK, Smith ML, Hessler P, et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer. 2017;17(1):399.
   PubMed Web of Science ®Google Scholar
• Guièze R, Liu VM, Rosebrock D, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36(4):369–384.e13.
   PubMed Web of Science ®Google Scholar
• Negi A, Murphy PV. Development of mcl-1 inhibitors for cancer therapy. Eur J Med Chem. 2021;210:113038.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Parker R, Zhang Y, et al. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms. BMC Cancer. 2018;18(1):1129.
   PubMedGoogle Scholar
• Wei AH, Roberts AW, Spencer A, et al. Targeting MCL-1 in hematologic malignancies: rationale and progress. Blood Rev. 2020;44:100672.
   PubMed Web of Science ®Google Scholar
• Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, et al. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased bax and bak expression. Clin Cancer Res. 2008;14(5):1550–1560.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14(5):1561–1570.
   PubMed Web of Science ®Google Scholar
• Carter BZ, Mak PY, Tao W, et al. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica. 2022;107(1):58–76.
   PubMed Web of Science ®Google Scholar
• Caenepeel S, Brown SP, Belmontes B, et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 2018;8(12):1582–1597.
   PubMed Web of Science ®Google Scholar
• Brennan MS, Chang C, Tai L, et al. Humanized mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use. Blood. 2018;132(15):1573–1583.
   PubMed Web of Science ®Google Scholar
• Tantawy SS, Hubner S, Tan Z, et al. Mechanisms of MCL-1 protein stability induced by MCL-1 antagonists in B-Cell malignancies. Clin Cancer Res. 2023;29(2):446–457.
   PubMed Web of Science ®Google Scholar
• Kotschy A, Szlavik Z, Murray J, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538(7626):477–482.
   PubMed Web of Science ®Google Scholar
• Yi X, Sarkar A, Kismali G, et al. AMG-176, an mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia. Clin Cancer Res. 2020;26(14):3856–3867.
   PubMed Web of Science ®Google Scholar
• Yi X, Jain N, Iles LR, et al. Targeting mcl-1 by AMG-176 during ibrutinib and venetoclax therapy in chronic lymphocytic leukemia. Front Oncol. 2022;12:833714.
   PubMed Web of Science ®Google Scholar
• Wang X, Bathina M, Lynch J, et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013;27(12):1351–1364.
   PubMed Web of Science ®Google Scholar
• Thomas RL, Roberts DJ, Kubli DA, et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 2013;27(12):1365–1377.
   PubMed Web of Science ®Google Scholar
• Perciavalle RM, Stewart DP, Koss B, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012;14(6):575–583.
   PubMed Web of Science ®Google Scholar
• Chen G, Magis AT, Xu K, et al. Targeting mcl-1 enhances DNA replication stress sensitivity to cancer therapy. J Clin Invest. 2018;128(1):500–516.
   PubMed Web of Science ®Google Scholar
• Germain M, Nguyen AP, Le Grand JN, et al. MCL-1 is a stress sensor that regulates autophagy in a developmentally regulated manner. Embo J. 2011;30(2):395–407.
   PubMed Web of Science ®Google Scholar
• Prukova D, Andera L, Nahacka Z, et al. Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin Cancer Res. 2019;25(14):4455–4465.
   PubMed Web of Science ®Google Scholar
• Phillips DC, Xiao Y, Lam LT, et al. Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015;5(11):e368.
   PubMedGoogle Scholar
• Zhao S, Kanagal-Shamanna R, Navsaria L, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020;95(6):623–629.
   PubMed Web of Science ®Google Scholar
• Ryu Y, Hall CP, Reynolds CP, et al. Caspase-dependent mcl-1 cleavage and effect of mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines. Exp Biol Med. 2014;239(10):1390–1402.
   Web of Science ®Google Scholar